Idiopathic noncirrhotic intrahepatic portal hypertension is an ongoing problem in India

[1]  Christopher D. Williams,et al.  Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial , 2011, Hepatology.

[2]  S. Sookoian,et al.  Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. , 2011, Atherosclerosis.

[3]  D. Valla,et al.  Idiopathic noncirrhotic portal hypertension , 2011, Hepatology.

[4]  B. Graubard,et al.  Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER‐medicare database , 2011, Hepatology.

[5]  C. Etzel,et al.  Genetics of lung cancer susceptibility and COPD. , 2011, The Lancet. Oncology.

[6]  S. Sookoian,et al.  Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease , 2011, Hepatology.

[7]  M. V. Oijen,et al.  Ribavirin concentration is a more important predictor of sustained viral response than anemia in hepatitis C patients. , 2011 .

[8]  I. Ng,et al.  Abstract 2445: CD24+ liver tumor-initiating cells drives self-renewal and tumor initiation through Stat3-mediated Nanog regulation , 2011 .

[9]  G. Fattovich,et al.  Complementary role of vitamin D deficiency and the interleukin‐28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C , 2011, Hepatology.

[10]  V. Paradis,et al.  Obliterative portal venopathy: portal hypertension is not always present at diagnosis. , 2011, Journal of hepatology.

[11]  B. Clotet,et al.  IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients , 2010, PloS one.

[12]  Cameron D. Palmer,et al.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease , 2010, Hepatology.

[13]  A. Zhu,et al.  Metabolic syndrome and hepatocellular carcinoma , 2009, Cancer.

[14]  Yang Liu,et al.  CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. , 2009, Trends in immunology.

[15]  G. Chandy,et al.  Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital , 2009, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[16]  S. Sookoian,et al.  Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. , 2009, Atherosclerosis.

[17]  C. la Vecchia,et al.  Estimates of the Incidence and Prevalence of Hepatocellular Carcinoma in Italy in 2002 and Projections for the Years 2007 and 2012 , 2009, Tumori.

[18]  B. George,et al.  Aetiology of paediatric portal hypertension – experience of a tertiary care centre in South India , 2009, Tropical doctor.

[19]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[20]  A. Morris,et al.  Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis , 2008, The American journal of clinical nutrition.

[21]  G. di Perri,et al.  The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. , 2008, The Journal of antimicrobial chemotherapy.

[22]  Yang Liu,et al.  CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. , 2007, Trends in immunology.

[23]  C. la Vecchia,et al.  Hepatitis Viruses, Alcohol, and Tobacco in the Etiology of Hepatocellular Carcinoma in Italy , 2006, Cancer Epidemiology Biomarkers & Prevention.

[24]  S. Sookoian,et al.  A1166C Angiotensin II Type 1 Receptor Gene Polymorphism May Predict Hemodynamic Response to Losartan in Patients with Cirrhosis and Portal Hypertension , 2005, The American Journal of Gastroenterology.

[25]  J. Goedert,et al.  Infection with human herpes virus type 8 in an area at high prevalence for hepatitis C virus infection in southern Italy , 2004, Journal of viral hepatitis.

[26]  D. Valla,et al.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients , 2002, Gut.

[27]  Y. Chawla,et al.  Non‐cirrhotic portal fibrosis (idiopathic portal hypertension): Experience with 151 patients and a review of the literature , 2002, Journal of gastroenterology and hepatology.

[28]  T. Liang,et al.  The Association of Genetic Variability in PNPLA 3 with Histological Severity of Non-Alcoholic Fatty Liver Disease , 2011 .

[29]  X. Gu,et al.  An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population , 2009, Human Genetics.

[30]  C. la Vecchia,et al.  The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.